Abstract
The current treatment for hepatitis C virus (HCV) genotype 1 chronic infection is the addition of direct-acting antivirals (DAA) with a protease inhibitor (telaprevir or boceprevir) to the pegylated interferon (PEG-IFN) plus ribavirin (RBV) regimen. Major progress has been made in the past few years: numerous ongoing trials with different compounds, increasing sustained virological response (SVR) rates with oral regimens and shortened treatment duration. Combinations of antivirals with additive potency that lack cross-resistance and with a good safety profile may provide new regimens in the future to make HCV the first chronic viral infection to be eradicated worldwide with a finite duration of combination DAA therapy without IFN.
© 2012 John Wiley & Sons A/S.
MeSH terms
-
Antiviral Agents / adverse effects
-
Antiviral Agents / chemistry
-
Antiviral Agents / therapeutic use*
-
Drug Design
-
Drug Therapy, Combination
-
Genotype
-
Hepacivirus / drug effects*
-
Hepacivirus / enzymology
-
Hepacivirus / genetics
-
Hepatitis C, Chronic / diagnosis
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / therapeutic use
-
Models, Molecular
-
Molecular Structure
-
Polyethylene Glycols / therapeutic use
-
Recombinant Proteins / therapeutic use
-
Ribavirin / therapeutic use
-
Serine Proteinase Inhibitors / adverse effects
-
Serine Proteinase Inhibitors / chemistry
-
Serine Proteinase Inhibitors / therapeutic use*
-
Treatment Outcome
-
Viral Nonstructural Proteins / antagonists & inhibitors
Substances
-
Antiviral Agents
-
Interferon alpha-2
-
Interferon-alpha
-
NS3 protein, hepatitis C virus
-
NS4 protein, hepatitis C virus
-
Recombinant Proteins
-
Serine Proteinase Inhibitors
-
Viral Nonstructural Proteins
-
Polyethylene Glycols
-
Ribavirin
-
NS-5 protein, hepatitis C virus
-
peginterferon alfa-2b
-
peginterferon alfa-2a